A 13-week subchronic toxicity study of an Eriobotrya japonica leaf extract in rats

• Published in: Journal of ethnopharmacology Vol. 226; pp. 1 - 10
• Main Authors: Seong, Nak-Won, Seo, Heung-Sik, Kim, Jun-Ho, Kim, Yong-Jae, Kim, Eun, Lee, Joon-Yeol, Ko, Je-Won, Kim, Jong-Choon
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 15.11.2018
• Subjects: No-observed-adverse-effect level; Repeated oral dose toxicity; Rosaceae; Target organ; EJE; Rosaceae; Target organ; MFDS; No-observed-adverse-effect level; SD; RBC; OECD; Repeated oral dose toxicity; HCT; WBC; Hb; HPLC
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2018.07.024

Eriobotrya japonica leaf is widely used in traditional medicine, and exhibits various beneficial effects such as anti-inflammatory, antiviral, antioxidant, and antitumor activities. However, limited data are available on the potential adverse effects of E. japonica. This study investigated the potential subchronic toxicity of an E. japonica leaf extract (EJE) through a 13-week repeated oral dose experiment in Sprague–Dawley rats. Forty male and 40 female rats were randomly assigned to four experimental groups: three treatment groups receiving 250, 500, and 1000 mg/kg/day of EJE and a vehicle control group receiving sterile distilled water for 13 weeks. Repeated oral administration of EJE for 13 weeks did not cause any treatment-related adverse effects with respect to clinical symptoms, body weight, food and water consumption, urinalysis, ophthalmology, necropsy findings, hematology, serum biochemistry, organ weight, and histopathological examination at any dose tested. Although some changes were observed in clinical symptoms, organ weight, hematology, and histopathology, these findings did not show a dose–response relationship and were within normal historical ranges for control rats. Under the present experimental conditions, the no-observed-adverse-effect level of EJE was > 1000 mg/kg/day in both sexes and no target organs were identified. The results suggest that the EJE is a safe traditional medicine for clinical applications at proper dose. [Display omitted]